Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication ...

The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...

BofA outlines risks and upside for managed care stocks, favoring Cigna and Alignment while flagging Medicare and Medicaid ...

A wave of transformative US drug-pricing agreements and record manufacturing investments from leading biopharmaceutical ...

The use of GLP-1 drugs to treat obesity has cause awareness of the complex medical condition to surge. But the cost of ...